OVERVIEW
Current influenza vaccines need annual updates and likely provide minimal protection from a novel pandemic influenza. The Influenza Vaccine Innovation program will develop novel vaccines that can enable earlier, broader, and more durable protection with an ultimate goal of protecting against both seasonal and pandemic influenza.
APPROACH
This program is a joint venture with BARDA DRIVe and the Influenza and Emerging Infectious Diseases Division (IEIDD), to support the development of commercially viable products that are faster, more easily deployed, and/or more effective than currently available influenza vaccines. The program will consider innovations that would allow a vaccine to be used effectively prior to a pandemic, or deployed more easily during a pandemic.
This includes technologies that:
- Provide protection against pandemic and seasonal viruses
- Use oral, intranasal, or inhaled delivery routes
- Extend the duration of protection provided by influenza vaccines to at least one year
Program Goals
Enhanced Protection
New formulations to protect against pandemic and seasonal influenza, possibly preventing or diminishing transmission
Improved Delivery
Dose sparing, including single-dose efficacy and new delivery modalities, for easier administration
Longer Lasting Protection
Vaccines that provide at least one year of immunity to influenza
INFLUENZA VACCINE INNOVATION
Funding
closes
1/20/25
For more information on this program, email:
Learn about a complementary influenza vaccine opportunity for TRL 6 or above with IEIDD (BAA AOI #8)